KRO has put in a striking 22% gain over the past month — but the move has done almost nothing to dent short conviction, and earnings are one week away.
The price recovery has been broad-based across commodity chemicals this week. Closest peer TROX rose 7% on the week, CC gained 8.7%, and OEC climbed nearly 11%. Kronos kept pace with an 8.2% weekly gain, closing Tuesday at $7.80, suggesting the sector is catching a bid rather than any KRO-specific re-rating. What makes this week interesting is the contrast between a stock that has rallied sharply and a short base that has quietly rebuilt — the two are now on a collision course ahead of the May 13 Q1 earnings call.
Short positioning has moved in the wrong direction for bulls. Short interest as a percentage of free float runs at 8.6% — well above a trivial level — and the absolute share count has risen 6.4% over the past week alone, adding roughly 108,000 shares. Zooming out, the short book contracted sharply through mid-April, falling from around 2.1 million shares in late March to a trough near 1.55 million on April 21, before resuming its climb. That reversal — shorts rebuilding exactly as the stock recovered — signals a cohort of sellers who are leaning into the rally rather than covering into it. The ORTEX short score has drifted higher too, moving from 49.3 on April 22 to 53.5 by May 5. Not extreme, but directionally clear. Days to cover registers at 5.8 by the official FINRA fortnightly count, meaning any forced covering would take time to work through.
Borrow conditions tell a looser story, which is the sharpest contradiction in the setup. Cost to borrow has fallen 17% this week to 0.40% — the cheapest it has been in at least 30 days — and availability is wide at 673% of short interest, meaning there is roughly six times as much stock available to lend as is currently lent out. That is far from tight. Utilization runs at only 13.4%, well below the 52-week peak of 29%. Put simply: shorts are adding, but they face no pressure from the lending market. The borrow is cheap and plentiful, removing one of the usual catalysts for a covering squeeze. Options reinforce the bullish lean on the tape — the put/call ratio is at 0.07, near its 52-week low of 0.064, and almost one standard deviation below its 20-day average of 0.22. Calls heavily dominate activity right now, consistent with the recent price momentum.
The Street has been bearish on KRO for some time, and the most recent analyst data — though flagged as stale at roughly five months old — reflects persistent negativity. Goldman Sachs carried a Sell rating with a $5 target in December 2025, and Barclays held an Underweight. With KRO trading at $7.80, the stock is already meaningfully above both cited targets, suggesting either the thesis has shifted in recent months or fresh coverage is needed. The analyst return potential metric registers at -25.9%, implying the consensus target remains well below spot. EV/EBITDA is modest at 4.8x, and the earnings yield factor sits in the top decile of its universe (EPS surprise ranked at the 91st percentile), giving fundamental longs something to work with. Relative strength has been strong: the stock is up 68% year-to-date.
Ownership structure is dominated by Contran Corporation, which controls 81% of the float — leaving very little freely traded stock for the short base to work with. That tight float dynamic amplifies any sentiment shift around earnings. The most recent earnings history shows the stock dipped roughly 1% the next day after the March 2026 result and gave back 3.4% over the following five days — a mild negative reaction rather than a violent one, but a pattern of fading the print rather than building on it.
With Q1 results due May 13, the week ahead turns on whether the momentum in the stock price is backed by improving titanium dioxide fundamentals or whether the rally — carried largely by the sector — runs into a cautious print that gives the rebuilding short base its first real test.
See the live data behind this article on ORTEX.
Open KRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
